Reproductive and developmental toxicity studies are critical for identifying risks to fertility, embryonic development, and offspring viability. These studies provide essential safety data for compounds intended for chronic use, especially in populations of reproductive age or during pregnancy. For IND-enabling toxicology, the design of reproductive studies is governed by ICH guidelines such as ICH S5(R3),…
Nanoparticle-based drug delivery systems have transformed the pharmaceutical landscape by enabling targeted, controlled, and efficient transport of therapeutic agents. However, the unique physicochemical properties of nanoparticles—such as high surface area, reactivity, and cellular penetration—also introduce distinct toxicological challenges that must be addressed during IND-enabling studies. The biocompatibility, biodistribution, and clearance of nanoparticles depend on their…
Genotoxicity testing is an essential part of preclinical safety assessment, designed to evaluate the potential of a compound to cause damage to genetic material. This includes point mutations, chromosomal fragmentation, and structural rearrangements, all of which may contribute to carcinogenicity or heritable defects. Genotoxicity assays are typically performed early in the IND-enabling toxicology process, often…
Endocrine disruptors are exogenous substances that interfere with the normal function of hormonal systems, potentially causing developmental, reproductive, neurological, or immune effects in humans and wildlife. Regulatory concern over endocrine-disrupting chemicals (EDCs) has led to the implementation of structured screening and testing frameworks by agencies such as the U.S. Environmental Protection Agency (EPA) and the…
Quantitative structure–activity relationship (QSAR) modeling represents a computational method used to predict the biological activity or toxicity of chemical compounds based on their molecular structure. In regulatory toxicology, QSAR tools are increasingly employed for early hazard identification, prioritization of test compounds, and support for read-across approaches when experimental data are limited. These models provide a…
Understanding the distinction between systemic and local toxicity is a cornerstone of preclinical toxicology study design. Systemic toxicity refers to adverse effects that occur at sites distant from the point of contact or administration, typically resulting from systemic distribution through the bloodstream. In contrast, local toxicity involves direct damage at or near the site of…
Sex-based biological differences significantly influence drug metabolism, pharmacokinetics, and toxicological outcomes. While many toxicology studies historically used male animals to reduce variability, current regulatory guidance emphasizes the importance of including both sexes to detect potential sex-specific toxicities. This is particularly important for compounds affecting hormonal pathways, reproductive systems, or metabolism, where male and female animals…
Inhalation toxicology is essential for evaluating the safety of compounds delivered via respiratory exposure, whether intentionally (e.g., inhaled drugs) or incidentally (e.g., aerosols, industrial particulates). The design and interpretation of inhalation studies present unique challenges compared to oral or parenteral routes, particularly with respect to dose uniformity, particle size, and deposition patterns throughout the respiratory…
Physiologically-based pharmacokinetic (PBPK) modeling is a computational approach used to simulate the absorption, distribution, metabolism, and excretion (ADME) of compounds in humans and animals using anatomical and physiological parameters. In the context of IND submissions, PBPK models provide a powerful tool for bridging preclinical and clinical data, guiding dose selection, predicting tissue exposure, and informing…
Adverse Outcome Pathways (AOPs) represent a conceptual framework linking a molecular initiating event (MIE) to a series of biological key events (KEs) that lead to an adverse outcome (AO) at the organism or population level. This structured, mechanistic understanding of toxicity supports predictive modeling, risk assessment, and the development of alternative testing strategies. AOPs are…